Heterocyclic Quinolones – privileged pharmacophore for TB and Malaria
Webinar from AMG Global Compound Design series (May 2017) by Gemma Nixon, University of Liverpool. Her talk features heterocyclic quinolones as a privileged pharmacophore that can be used to target both mTB and malaria. She describes the process used to identify this class of molecule and presents data on their biological activity and drug-like properties. Promising results on treating TB were obtained from co-dosing with two quinolones that block different parts of the organism's respiratory chain.
AMG run monthly webinars on drug design for scientists involved in global health drug discovery, particularly those funded by the Bill & Melinda Gates Foundation.
For full details, supplementary information, including slide sets, and registration for upcoming webinars see www.mmv.org
